Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Read now
Alison Stopeck, Adam Brufsky, Lisa Kennedy, Sumi Bhatta, Debajyoti Bhowmik, Jacqueline Buchanan, Nicolas Despiegel & Guy Hechmati. (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics 23:1, pages 37-47.
Read now
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Noopur Raje, Garson David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Evangelos Terpos, Lisa Kennedy, Lorenzo Sabatelli, Michele Intorcia & Guy Hechmati. (2018) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics 21:5, pages 525-536.
Read now
Read now
D. V. Byreddy, M. F. Bouchonville II & E. M. Lewiecki. (2015) Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. Climacteric 18:sup2, pages 39-46.
Read now
Read now
Athanasios Dellis & Athanasios G Papatsoris. (2014) Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer. Expert Opinion on Biological Therapy 14:1, pages 7-10.
Read now
Read now
Articles from other publishers (28)
Charles B. Nguyen, Christopher Kobe, Kyle E. Kumbier, Jordan Bauman, Jennifer A. Burns, Phoebe A. Tsao, Jordan B. Sparks, Ted A. Skolarus & Megan E.V. Caram. (2023) Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System. JCO Oncology Practice.
Crossref
Crossref
Aaron P. Mitchell, Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz-Snyderman, Azeez Farooki & Michael J. Morris. (2022) Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 26:1, pages 126-132.
Crossref
Crossref
Junjie Lu, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen & Bo Shuai. (2023) Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Frontiers in Oncology 13.
Crossref
Crossref
Kelly E. Anderson, Daniel Polsky, Sydney Dy & Aditi P. Sen. (2021)
Prescribing of low‐ versus
high‐cost
Part B drugs in Medicare Advantage and traditional Medicare
. Health Services Research 57:3, pages 537-547.
Crossref
Crossref
Aaron P Mitchell, Akriti Mishra Meza, Katherine S Panageas, Allison Lipitz-Snyderman, Peter B Bach & Michael J Morris. (2022) Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. JNCI: Journal of the National Cancer Institute 114:3, pages 419-426.
Crossref
Crossref
Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L. Ng & Kednapa Thavorn. (2021) Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology 28:3, pages 1847-1856.
Crossref
Crossref
Takazumi Yasui, Moemi Kimura, Hiroki Nagamine, Shosuke Yajima, Takeshi Karube, Hitoshi Sato, Seiji Asoda, Satoshi Hara & Katsuhiro Onizawa. (2021) Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 131:3, pages 312-318.
Crossref
Crossref
Katie L. Owen & Belinda S. Parker. (2019) Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. Molecular Immunology 110, pages 57-68.
Crossref
Crossref
Jessica Y. Matuoka, James G. Kahn & Silvia R. Secoli. (2018) Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European Journal of Health Economics 20:4, pages 487-499.
Crossref
Crossref
Diomidis Kozyrakis, Dionyssios Paridis, Stefanos Perikleous, Konstantinos Malizos, Anastasios Zarkadas & Antonios Tsagkalis. (2018) The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer. Advances in Urology 2018, pages 1-9.
Crossref
Crossref
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg & Judith Dams. (2018) Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLOS ONE 13:12, pages e0208063.
Crossref
Crossref
Lazaros Andronis, Ilias Goranitis, Sue Bayliss & Rui Duarte. (2017) Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. PharmacoEconomics 36:3, pages 301-322.
Crossref
Crossref
Eva Mercier, Daniel Velasco, Marta Cabezas, Cristina Agut & Meritxell Villalon. (2018) Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. Journal of Health Economics and Outcomes Research, pages 1-14.
Crossref
Crossref
Eva Tirado, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut & Meritxell Granell Villalón. (2018) Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. Journal of Health Economics and Outcomes Research 6:1, pages 1-14.
Crossref
Crossref
. 2018. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
721
796
.
Jan Norum & Carsten Nieder. (2017) Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. PharmacoEconomics 35:12, pages 1223-1236.
Crossref
Crossref
Aaron A. Laviana, Stephanie C. Pannell, Kathy H.Y. Huen & Jonathan Bergman. (2017) Engaging patients in complex clinical decision-making: Successes, pitfalls, and future directions. Urologic Oncology: Seminars and Original Investigations 35:9, pages 569-573.
Crossref
Crossref
S.F. Miler, C.Y. Thomas & Y. Shiozawa. 2017. Introduction to Cancer Metastasis. Introduction to Cancer Metastasis
263
276
.
Gerhardt Attard, Chris Parker, Ros A Eeles, Fritz Schröder, Scott A Tomlins, Ian Tannock, Charles G Drake & Johann S de Bono. (2016) Prostate cancer. The Lancet 387:10013, pages 70-82.
Crossref
Crossref
Joseph F. LevyPatrick D. MeekMarjorie A. Rosenberg. (2014) US-Based Drug Cost Parameter Estimation for Economic Evaluations. Medical Decision Making 35:5, pages 622-632.
Crossref
Crossref
. 2015. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
675
747
.
Antonio Cano, José Manuel Silvan, Antonio Estévez, Francesc Baró, José Villero, Francisco Quereda, Javier Ferrer, Nicolás Mendoza & Rafael Sánchez-Borrego. (2014) Spanish Menopause Society position statement: Use of denosumab in postmenopausal women. Maturitas 79:1, pages 117-121.
Crossref
Crossref
Benjamin A. Gartrell & Fred Saad. (2014) Managing bone metastases and reducing skeletal related events in prostate cancer. Nature Reviews Clinical Oncology 11:6, pages 335-345.
Crossref
Crossref
Benjamin A. Gartrell, Robert E. Coleman, Karim Fizazi, Kurt Miller, Fred Saad, Cora N. Sternberg & Matthew D. Galsky. (2014) Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer. European Urology 65:2, pages 278-286.
Crossref
Crossref
Christoph Domschke & Florian Schuetz. (2014) Side Effects of Bone-Targeted Therapies in Advanced Breast Cancer. Breast Care 9:5, pages 332-336.
Crossref
Crossref
Thomas Roza, Lukman Hakim, Hendrik van Poppel & Steven Joniau. (2013) Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions. Drugs & Aging 30:11, pages 877-886.
Crossref
Crossref
Sathana DushyanthenDavina A.F. CossignyGerald M.Y. Quan. (2013) The Osteoblastic and Osteoclastic Interactions in Spinal Metastases Secondary to Prostate Cancer. Cancer Growth and Metastasis 6, pages CGM.S12769.
Crossref
Crossref
Shiran Ferber, Galia Tiram & Ronit Satchi-Fainaro. 2013. Cancer Targeted Drug Delivery. Cancer Targeted Drug Delivery
509
542
.